Cancer Research, volume 79, issue 20, pages 5131-5139

Roles and Regulation of Long Noncoding RNAs in Hepatocellular Carcinoma

Wong Samuel Y.S. 1
Huang Feiyang 2
Lim Lee Jin 1, 3, 4
Chong Samuel S. 5
Ooi London Lucien 6, 7
Kon Oi Lian 1
Lee Caroline 1, 3, 6, 8
1
 
2Division of Cellular and Molecular Research, Humphrey Oei Institute of Cancer Research, National Cancer Centre Singapore, Singapore, Singapore.
2
 
3NUS High School of Math and Science, Singapore, Singapore.
4
 
4Raffles Institution, Singapore, Singapore.
6
 
6Duke-NUS Graduate Medical School, Singapore, Singapore.
7
 
7Department of Hepato-Pancreato-Biliary and Transplant Surgery, Singapore General Hospital, Singapore, Singapore.
Publication typeJournal Article
Publication date2019-10-15
Journal: Cancer Research
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor11.2
ISSN00085472, 15387445
Cancer Research
Oncology
Abstract

Next-generation sequencing has uncovered thousands of long noncoding RNAs (lncRNA). Many are reported to be aberrantly expressed in various cancers, including hepatocellular carcinoma (HCC), and play key roles in tumorigenesis. This review provides an in-depth discussion of the oncogenic mechanisms reported to be associated with deregulated HCC-associated lncRNAs. Transcriptional expression of lncRNAs in HCC is modulated through transcription factors, or epigenetically by aberrant histone acetylation or DNA methylation, and posttranscriptionally by lncRNA transcript stability modulated by miRNAs and RNA-binding proteins. Seventy-four deregulated lncRNAs have been identified in HCC, of which, 52 are upregulated. This review maps the oncogenic roles of these deregulated lncRNAs by integrating diverse datasets including clinicopathologic features, affected cancer phenotypes, associated miRNA and/or protein-interacting partners as well as modulated gene/protein expression. Notably, 63 deregulated lncRNAs are significantly associated with clinicopathologic features of HCC. Twenty-three deregulated lncRNAs associated with both tumor and metastatic clinical features were also tumorigenic and prometastatic in experimental models of HCC, and eight of these mapped to known cancer pathways. Fifty-two upregulated lncRNAs exhibit oncogenic properties and are associated with prominent hallmarks of cancer, whereas 22 downregulated lncRNAs have tumor-suppressive properties. Aberrantly expressed lncRNAs in HCC exert pleiotropic effects on miRNAs, mRNAs, and proteins. They affect multiple cancer phenotypes by altering miRNA and mRNA expression and stability, as well as through effects on protein expression, degradation, structure, or interactions with transcriptional regulators. Hence, these insights reveal novel lncRNAs as potential biomarkers and may enable the design of precision therapy for HCC.

Citations by journals

1
2
3
4
5
6
7
Frontiers in Oncology
Frontiers in Oncology, 7, 5.22%
Frontiers in Oncology
7 publications, 5.22%
Journal of Oncology
Journal of Oncology, 5, 3.73%
Journal of Oncology
5 publications, 3.73%
Aging
Aging, 4, 2.99%
Aging
4 publications, 2.99%
Oncology Letters
Oncology Letters, 3, 2.24%
Oncology Letters
3 publications, 2.24%
Cancers
Cancers, 3, 2.24%
Cancers
3 publications, 2.24%
Frontiers in Cell and Developmental Biology
Frontiers in Cell and Developmental Biology, 3, 2.24%
Frontiers in Cell and Developmental Biology
3 publications, 2.24%
Biomedicine and Pharmacotherapy
Biomedicine and Pharmacotherapy, 3, 2.24%
Biomedicine and Pharmacotherapy
3 publications, 2.24%
Journal of Cellular and Molecular Medicine
Journal of Cellular and Molecular Medicine, 3, 2.24%
Journal of Cellular and Molecular Medicine
3 publications, 2.24%
Bioengineered
Bioengineered, 3, 2.24%
Bioengineered
3 publications, 2.24%
Biomedicines
Biomedicines, 2, 1.49%
Biomedicines
2 publications, 1.49%
Molecular Medicine Reports
Molecular Medicine Reports, 2, 1.49%
Molecular Medicine Reports
2 publications, 1.49%
World Journal of Gastroenterology
World Journal of Gastroenterology, 2, 1.49%
World Journal of Gastroenterology
2 publications, 1.49%
Frontiers in Genetics
Frontiers in Genetics, 2, 1.49%
Frontiers in Genetics
2 publications, 1.49%
BMC Cancer
BMC Cancer, 2, 1.49%
BMC Cancer
2 publications, 1.49%
Journal of Experimental and Clinical Cancer Research
Journal of Experimental and Clinical Cancer Research, 2, 1.49%
Journal of Experimental and Clinical Cancer Research
2 publications, 1.49%
Human Cell
Human Cell, 2, 1.49%
Human Cell
2 publications, 1.49%
Cell Death Discovery
Cell Death Discovery, 2, 1.49%
Cell Death Discovery
2 publications, 1.49%
Archives of Medical Research
Archives of Medical Research, 2, 1.49%
Archives of Medical Research
2 publications, 1.49%
Pathology Research and Practice
Pathology Research and Practice, 2, 1.49%
Pathology Research and Practice
2 publications, 1.49%
Liver International
Liver International, 2, 1.49%
Liver International
2 publications, 1.49%
Journal of Hepatocellular Carcinoma
Journal of Hepatocellular Carcinoma, 2, 1.49%
Journal of Hepatocellular Carcinoma
2 publications, 1.49%
Disease Markers
Disease Markers, 2, 1.49%
Disease Markers
2 publications, 1.49%
Heliyon
Heliyon, 2, 1.49%
Heliyon
2 publications, 1.49%
Translational Cancer Research
Translational Cancer Research, 2, 1.49%
Translational Cancer Research
2 publications, 1.49%
Journal of Cancer Research and Clinical Oncology
Journal of Cancer Research and Clinical Oncology, 1, 0.75%
Journal of Cancer Research and Clinical Oncology
1 publication, 0.75%
Doklady Biochemistry and Biophysics
Doklady Biochemistry and Biophysics, 1, 0.75%
Doklady Biochemistry and Biophysics
1 publication, 0.75%
Epigenomics
Epigenomics, 1, 0.75%
Epigenomics
1 publication, 0.75%
Biomarkers in Medicine
Biomarkers in Medicine, 1, 0.75%
Biomarkers in Medicine
1 publication, 0.75%
DNA and Cell Biology
DNA and Cell Biology, 1, 0.75%
DNA and Cell Biology
1 publication, 0.75%
1
2
3
4
5
6
7

Citations by publishers

5
10
15
20
25
Springer Nature
Springer Nature, 22, 16.42%
Springer Nature
22 publications, 16.42%
Elsevier
Elsevier, 22, 16.42%
Elsevier
22 publications, 16.42%
Frontiers Media S.A.
Frontiers Media S.A., 18, 13.43%
Frontiers Media S.A.
18 publications, 13.43%
Hindawi Limited
Hindawi Limited, 14, 10.45%
Hindawi Limited
14 publications, 10.45%
Wiley
Wiley, 13, 9.7%
Wiley
13 publications, 9.7%
Multidisciplinary Digital Publishing Institute (MDPI)
Multidisciplinary Digital Publishing Institute (MDPI), 7, 5.22%
Multidisciplinary Digital Publishing Institute (MDPI)
7 publications, 5.22%
Spandidos Publications
Spandidos Publications, 7, 5.22%
Spandidos Publications
7 publications, 5.22%
Impact Journals
Impact Journals, 4, 2.99%
Impact Journals
4 publications, 2.99%
Baishideng Publishing Group
Baishideng Publishing Group, 4, 2.99%
Baishideng Publishing Group
4 publications, 2.99%
Taylor & Francis
Taylor & Francis, 4, 2.99%
Taylor & Francis
4 publications, 2.99%
AME Publishing Company
AME Publishing Company, 4, 2.99%
AME Publishing Company
4 publications, 2.99%
Future Medicine
Future Medicine, 3, 2.24%
Future Medicine
3 publications, 2.24%
Dove Medical Press
Dove Medical Press, 3, 2.24%
Dove Medical Press
3 publications, 2.24%
Pleiades Publishing
Pleiades Publishing, 1, 0.75%
Pleiades Publishing
1 publication, 0.75%
Mary Ann Liebert
Mary Ann Liebert, 1, 0.75%
Mary Ann Liebert
1 publication, 0.75%
Public Library of Science (PLoS)
Public Library of Science (PLoS), 1, 0.75%
Public Library of Science (PLoS)
1 publication, 0.75%
Federation of American Societies for Experimental Biology (FASEB)
Federation of American Societies for Experimental Biology (FASEB), 1, 0.75%
Federation of American Societies for Experimental Biology (FASEB)
1 publication, 0.75%
Walter de Gruyter
Walter de Gruyter, 1, 0.75%
Walter de Gruyter
1 publication, 0.75%
Oxford University Press
Oxford University Press, 1, 0.75%
Oxford University Press
1 publication, 0.75%
Begell House
Begell House, 1, 0.75%
Begell House
1 publication, 0.75%
5
10
15
20
25
  • We do not take into account publications that without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
Wong S. Y. et al. Roles and Regulation of Long Noncoding RNAs in Hepatocellular Carcinoma // Cancer Research. 2019. Vol. 79. No. 20. pp. 5131-5139.
GOST all authors (up to 50) Copy
Wong S. Y., Huang F., Lim L. J., Chong S. S., Ooi L. L., Kon O. L., Lee C. Roles and Regulation of Long Noncoding RNAs in Hepatocellular Carcinoma // Cancer Research. 2019. Vol. 79. No. 20. pp. 5131-5139.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1158/0008-5472.CAN-19-0255
UR - https://doi.org/10.1158%2F0008-5472.CAN-19-0255
TI - Roles and Regulation of Long Noncoding RNAs in Hepatocellular Carcinoma
T2 - Cancer Research
AU - Lim, Lee Jin
AU - Wong, Samuel Y.S.
AU - Huang, Feiyang
AU - Chong, Samuel S.
AU - Ooi, London Lucien
AU - Kon, Oi Lian
AU - Lee, Caroline
PY - 2019
DA - 2019/10/15 00:00:00
PB - American Association for Cancer Research (AACR)
SP - 5131-5139
IS - 20
VL - 79
SN - 0008-5472
SN - 1538-7445
ER -
BibTex |
Cite this
BibTex Copy
@article{2019_Wong,
author = {Lee Jin Lim and Samuel Y.S. Wong and Feiyang Huang and Samuel S. Chong and London Lucien Ooi and Oi Lian Kon and Caroline Lee},
title = {Roles and Regulation of Long Noncoding RNAs in Hepatocellular Carcinoma},
journal = {Cancer Research},
year = {2019},
volume = {79},
publisher = {American Association for Cancer Research (AACR)},
month = {oct},
url = {https://doi.org/10.1158%2F0008-5472.CAN-19-0255},
number = {20},
pages = {5131--5139},
doi = {10.1158/0008-5472.CAN-19-0255}
}
MLA
Cite this
MLA Copy
Wong, Samuel Y.S., et al. “Roles and Regulation of Long Noncoding RNAs in Hepatocellular Carcinoma.” Cancer Research, vol. 79, no. 20, Oct. 2019, pp. 5131-5139. https://doi.org/10.1158%2F0008-5472.CAN-19-0255.
Found error?
Profiles